The Article related to preparation heterocyclic ph carboxamide compound inhibitor histone deacetylase therapy, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Amides, Amidines, Imidic Esters, Hydrazides, and Hydrazonic Esters and other aspects.Reference of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride
On November 1, 2012, Holson, Edward; Wagner, Florence Fevrier; Weiwer, Michel published a patent.Reference of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride The title of the patent was Preparation of heterocyclic phenyl carboxamide compounds as inhibitors of histone deacetylase for therapy. And the patent contained the following:
The present invention relates to compounds of formula I, or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U is (un)substituted CH2-CH2, (un)substituted NH, (un)substituted NH-NH-, and O; J is NH2, OH, and SH; V is C and N, with provisos; X is H, deuterium, Me, CF3, and halo; R2a, R2b, and R2c are independently H, halo, OH, NH2, and C1-8 alkyl; R5 is H, deuterium, halo, OH, C1-8 alkyloxy, etc.; and t = 0-3. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurol. disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematol. diseases, and neoplastic diseases in humans and animals. Synthetic procedures for preparing I are exemplified. Example compound II was prepared in a multistep synthetic scheme that involved reaction of tetrahydro-2H-pyran-4-carboxylic acid with tert-Bu [2-amino-4-(thiophen-2-yl)phenyl]carbamate and deprotection of the intermediate formed to give II. II had IC50 values between 1.1 and 5 μM in assays measuring HDAC1 and HDAC3 inhibition and between .11 and 1 μM in an HDA2 inhibition assay following a trypsin-coupled protocol. The experimental process involved the reaction of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride(cas: 1187830-46-1).Reference of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride
The Article related to preparation heterocyclic ph carboxamide compound inhibitor histone deacetylase therapy, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Amides, Amidines, Imidic Esters, Hydrazides, and Hydrazonic Esters and other aspects.Reference of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia